First Tracks Biotherapeutics, Inc. (TRAX) stock
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
First Tracks Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $23.85M | -39.3% |
| Q2 FY2026 | Jun 30, 2026 | $25.64M | -38.2% |
| Q1 FY2026 | Mar 31, 2026 | $33.96M | – |
| Q3 FY2025 | Sep 30, 2025 | $33.32M | – |
| Q2 FY2025 | Jun 30, 2025 | $39.27M | – |
| Q1 FY2025 | Mar 31, 2025 | $41.47M | – |
See a number that looks wrong?